These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19238604)

  • 21. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers.
    Schelleman H; Klungel OH; Witteman JC; Breteler MM; Yazdanpanah M; Danser AH; Hofman A; van Duijn CM; de Boer A; Stricker BH
    Eur J Hum Genet; 2007 Apr; 15(4):478-84. PubMed ID: 17299437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ACP Journal Club. Review: Statins reduce mortality and cardiovascular (CV) morbidity in patients with low CV risk.
    Muñoz D; Granger CB
    Ann Intern Med; 2012 Apr; 156(8):JC4-07. PubMed ID: 22508747
    [No Abstract]   [Full Text] [Related]  

  • 23. ACP Journal Club. Daily n-3 fatty acid supplements did not reduce CV events in high-risk patients with dysglycemia.
    Lader E
    Ann Intern Med; 2012 Sep; 157(6):JC3-11. PubMed ID: 22986403
    [No Abstract]   [Full Text] [Related]  

  • 24. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ACP Journal Club. Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes.
    Lipscombe LL
    Ann Intern Med; 2009 Oct; 151(8):JC4-8. PubMed ID: 19841445
    [No Abstract]   [Full Text] [Related]  

  • 26. ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction.
    Ezekowitz JA; McAlister FA
    Ann Intern Med; 2009 May; 150(10):JC5-10. PubMed ID: 19451566
    [No Abstract]   [Full Text] [Related]  

  • 27. ACP Journal Club. Review: first-line low-dose thiazides and ACE inhibitors reduce mortality and morbidity in adults with hypertension.
    Shah NR; Ogedegbe G
    Ann Intern Med; 2010 Jan; 152(2):JC1-4. PubMed ID: 20083819
    [No Abstract]   [Full Text] [Related]  

  • 28. A perspective on telmisartan and cardiovascular risk.
    Giles TD
    Rev Cardiovasc Med; 2007; 8(3):154-9. PubMed ID: 17938615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ACP Journal Club. Daily multivitamin supplements did not reduce risk for major CV events over > 10 years in men.
    Fairfield KM
    Ann Intern Med; 2013 Feb; 158(4):JC8. PubMed ID: 23420255
    [No Abstract]   [Full Text] [Related]  

  • 30. ACP Journal Club. Review: Insulin to maintain normoglycemia within 24 hours of ischemic stroke does not reduce death or dependency.
    Wasielewski PG; Uchino K
    Ann Intern Med; 2011 Dec; 155(12):JC6-5. PubMed ID: 22184706
    [No Abstract]   [Full Text] [Related]  

  • 31. The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.
    Lamy A; Wang X; Gao P; Tong W; Gafni A; Dans A; Avezum A; Ferreira R; Young J; Yusuf S; Teo K;
    J Med Econ; 2011; 14(6):792-7. PubMed ID: 21981559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ACP Journal Club. Review: Counseling and educational methods that target multiple CV risk factors do not reduce mortality in adults without CHD.
    Patel MJ; Newby LK
    Ann Intern Med; 2011 Jun; 154(12):JC6-4. PubMed ID: 21690582
    [No Abstract]   [Full Text] [Related]  

  • 33. ACP Journal Club. Weekly INR self-testing did not reduce stroke, major bleeding, or death more than monthly clinic testing.
    Witt DM
    Ann Intern Med; 2011 Jan; 154(2):JC1-4, JC1-5. PubMed ID: 21242358
    [No Abstract]   [Full Text] [Related]  

  • 34. ACP Journal Club. Review: Intensive blood pressure control reduces stroke, but not mortality or MI, in type 2 diabetes.
    Moist L
    Ann Intern Med; 2013 Jan; 158(2):JC5. PubMed ID: 23318339
    [No Abstract]   [Full Text] [Related]  

  • 35. ACP Journal Club. Glargine did not reduce CV events more than standard care in patients with dysglycemia.
    Lader E
    Ann Intern Med; 2012 Sep; 157(6):JC3-10, JC3-11. PubMed ID: 22986402
    [No Abstract]   [Full Text] [Related]  

  • 36. ACP Journal Club. Valsartan reduced diabetes but not CV events in patients with impaired glucose tolerance and CV risk factors.
    Ann Intern Med; 2010 Jun; 152(12):JC6-9. PubMed ID: 20547903
    [No Abstract]   [Full Text] [Related]  

  • 37. ACP Journal Club. NSAIDs were associated with increased risk for mortality or recurrent MI in patients who had previous MI.
    Poses RM
    Ann Intern Med; 2011 Oct; 155(8):JC4-11. PubMed ID: 22007070
    [No Abstract]   [Full Text] [Related]  

  • 38. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
    Frederich R; Alexander JH; Fiedorek FT; Donovan M; Berglind N; Harris S; Chen R; Wolf R; Mahaffey KW
    Postgrad Med; 2010 May; 122(3):16-27. PubMed ID: 20463410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ACP Journal Club. Concomitant use of proton pump inhibitors with clopidogrel may increase risk for readmission after discharge for acute MI.
    Granger CB
    Ann Intern Med; 2009 Aug; 151(4):JC2-13. PubMed ID: 19687487
    [No Abstract]   [Full Text] [Related]  

  • 40. ACP Journal Club. Adding prompt revascularization to medical therapy did not reduce mortality or CV events in patients with type 2 diabetes and CAD.
    Poirier P
    Ann Intern Med; 2009 Oct; 151(8):JC4-5. PubMed ID: 19841443
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.